Please assess the completion status of the following clinical trial:

Trial Title: A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participants who enrolled in the initial study, and completed the primary vaccination.~* Able to understand the content of the additional informed consent and willing to sign the additional informed consent for the boosting study~* Able and willing to complete a one-month follow-up.~* HIV negative~* Axillary temperature ≤37.0°C on the day of enrollment~* General good health as established by medical history and physical examination.~Exclusion Criteria:~New occurrence of any of the following situation after the primary vaccination:~* Subject that has a medical history of any of the following: allergic history of any vaccination or drugs, or allergic to any ingredient of the Ad5-EBOV vaccine, such as mannitol~* Woman who become pregnant after the primary vaccination or is positive in β-HCG (human chorionic gonadotropin) pregnancy test (urine) on day of enrollment for the boosting study~* Any acute fever disease or infections in last 7 days~* Not well-controlled chronic illness, such as asthma, diabetes, or thyroid disease~* Hereditary angioneurotic edema or acquired angioneurotic edema~* Urticaria in last 6 months~* Asplenia or functional asplenia~* Platelet disorder or other bleeding disorder may cause injection contraindication~* Faint at the sight of blood or needles.~* Prior administration of immunodepressant or corticosteroids, antianaphylaxis treatment, cytotoxic treatment in last 6 months~* Prior administration of blood products in last 4 months~* Prior administration of other research medicines in last 1 month~* Prior administration of attenuated vaccine in last 1 month~* Prior administration of inactivated vaccine in last 14 days~* Current anti-tuberculosis prophylaxis or therapy~* Any condition that in the opinion of the investigators may interfere with the evaluation of study objectives

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- low dose group (Type: EXPERIMENTAL): 4×10\^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)
- high dose group (Type: EXPERIMENTAL): 1.6×10\^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)
- placebo group (Type: PLACEBO_COMPARATOR): placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).